Craft

CureVac

Stock Price

$3.1

2024-05-14

Market Capitalization

$695.3 M

2024-05-14

Revenue

€53.8 M

FY, 2023

CureVac Summary

Company Summary

Overview
CureVac is a biotechnology company offering messenger RNA (mRNA) technology. It develops mRNA-based prophylactic vaccines addressing infectious diseases, RNA-based cancer immunotherapies, and molecular therapies.
Type
Public
Status
Active
Founded
2000
HQ
Tübingen, DE | view all locations
Website
https://www.curevac.com/en/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Ingmar Hoerr
  • Pierre Kemula

    Pierre Kemula, Chief Financial Officer

  • Malte Greune

    Malte Greune, Chief Operating Officer

  • Myriam Mendila

    Myriam Mendila, Chief Development Officer

Operating MetricsView all

Patent Applications

500

Mar, 2020

Pre-Clinical Discovery Phase Products

17
183.3%

Jun, 2023

Pre-Clinical Development Phase Products

7

Jun, 2023

LocationsView all

6 locations detected

  • Tübingen, BW HQ

    Germany

    Friedrich-Miescher-Straße 15

  • Boston, MA

    United States

    250 Summer St 3rd Fl

  • Ottignies-Louvain-la-Neuve, Région Wallonne

    Belgium

    Av. Jean Monnet 4

  • Wiesbaden, HE

    Germany

    Leipziger Str. 35

  • Amsterdam, NH

    Netherlands

    Science Park 106

  • Basel, BS

    Switzerland

    Wartenbergstrasse 40

CureVac Financials

Summary Financials

Revenue (FY, 2023)
€53.8M
Gross profit (FY, 2023)
(€21.7M)
Net income (FY, 2023)
(€260.2M)
Cash (FY, 2023)
€402.5M
EBIT (FY, 2023)
(€275.4M)
Enterprise value
$380.4M

Footer menu